MX2013013800A - Oligodesoxinucleotidos inmunoestimuladores. - Google Patents

Oligodesoxinucleotidos inmunoestimuladores.

Info

Publication number
MX2013013800A
MX2013013800A MX2013013800A MX2013013800A MX2013013800A MX 2013013800 A MX2013013800 A MX 2013013800A MX 2013013800 A MX2013013800 A MX 2013013800A MX 2013013800 A MX2013013800 A MX 2013013800A MX 2013013800 A MX2013013800 A MX 2013013800A
Authority
MX
Mexico
Prior art keywords
oligodeoxynucleotides
immunostimulatory oligodeoxynucleotides
immunostimulatory
methods
vaccines
Prior art date
Application number
MX2013013800A
Other languages
English (en)
Other versions
MX346596B (es
Inventor
Carla Christina Schrier
Thomas Simon Ilg
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of MX2013013800A publication Critical patent/MX2013013800A/es
Publication of MX346596B publication Critical patent/MX346596B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/311—Phosphotriesters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a oligodesoxinucleótidos inmunoestimuladores, vectores y vacunas que comprenden dichos oligodesoxinucleótidos, a su uso como un medicamento, a su uso para la prevención o lucha contra enfermedades infecciosas, a métodos para la detección de dichos oligodesoxinucleótidos y a las células que se van a utilizar en estos métodos.
MX2013013800A 2011-05-26 2012-05-25 Oligodesoxinucleotidos inmunoestimuladores. MX346596B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161490380P 2011-05-26 2011-05-26
EP11167602 2011-05-26
PCT/EP2012/059797 WO2012160183A1 (en) 2011-05-26 2012-05-25 Immunostimulatory oligodeoxynucleotides

Publications (2)

Publication Number Publication Date
MX2013013800A true MX2013013800A (es) 2013-12-16
MX346596B MX346596B (es) 2017-03-23

Family

ID=47216635

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013800A MX346596B (es) 2011-05-26 2012-05-25 Oligodesoxinucleotidos inmunoestimuladores.

Country Status (10)

Country Link
US (1) US9359602B2 (es)
EP (1) EP2714907B1 (es)
JP (1) JP5872684B2 (es)
CN (1) CN103547674A (es)
BR (1) BR112013029968A2 (es)
CA (1) CA2834442A1 (es)
MX (1) MX346596B (es)
RU (1) RU2587633C2 (es)
WO (1) WO2012160183A1 (es)
ZA (1) ZA201308479B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012160183A1 (en) * 2011-05-26 2012-11-29 Intervet International B.V. Immunostimulatory oligodeoxynucleotides
AR091569A1 (es) 2012-06-28 2015-02-11 Intervet Int Bv Receptores de tipo toll
US20160136197A1 (en) 2013-06-14 2016-05-19 Intervet International B.V. Pharmaceutical Compositions Comprising a GPG Oligodeoxynucleotide and Cyclic Di-GMP
AR097029A1 (es) * 2013-07-26 2016-02-17 Intervet Int Bv Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune
RU2701808C2 (ru) 2014-10-03 2019-10-01 Интервет Интернэшнл Б.В. Вакцина широкого спектра действия против реовируса птиц
AU2016282879A1 (en) * 2015-06-26 2018-01-18 Bayer Animal Health Gmbh Methods of modulating cytosolic DNA surveillance molecules
CN105567782B (zh) * 2016-01-29 2020-08-04 山东省农业科学院畜牧兽医研究所 鸡胚成纤维细胞在体外筛选CpG寡聚脱氧核苷酸活性分子中的应用
KR20200095479A (ko) 2017-12-04 2020-08-10 인터벳 인터내셔널 비.브이. 레플리콘 입자 및 오일 아주반트를 사용한 예방접종
WO2019115385A1 (en) * 2017-12-15 2019-06-20 Bayer Animal Health Gmbh Immunostimulatory compositions
EP3727431A1 (en) 2017-12-20 2020-10-28 Intervet International B.V. Improved diluent for cell-associated alphaherpesvirus vaccine
JP2022514307A (ja) 2018-12-20 2022-02-10 インターベット インターナショナル ベー． フェー． プライム－ブーストワクチン接種レジメン
US20230031097A1 (en) 2019-12-20 2023-02-02 Intervet Inc. Multivalent hvt vector vaccine
MX2023007634A (es) 2020-12-24 2023-07-14 Intervet Int Bv Vacuna de vector hvt multivalente.
WO2023213946A1 (en) 2022-05-05 2023-11-09 Intervet International B.V. New multivalent hvt vector vaccine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1296713T3 (da) * 2000-06-08 2004-01-26 Intercell Biomedizinische Forschungs & Entwicklungs Gmbh Immunstimulerende oligodeoxynukleotider
ATE411054T1 (de) * 2001-08-17 2008-10-15 Coley Pharm Gmbh Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung
DE60234375D1 (de) * 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
AU2003247880B2 (en) * 2002-07-03 2010-09-02 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AU2003297483B2 (en) * 2002-12-23 2010-11-18 Trisalus Life Sciences, Inc. Immunostimulatory sequence oligonucleotides and methods of using the same
CN1810970B (zh) * 2005-01-27 2011-05-18 长春华普生物技术有限公司 含CpG的单链脱氧核苷酸与其疫苗组合物及其应用
WO2007020017A1 (en) * 2005-08-12 2007-02-22 Bionostra, S.L. Composition for bird immunization administered by aerosol
DE102006031483B4 (de) 2006-07-07 2009-12-24 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Zellulärer Pyrogentest
AU2008283802A1 (en) * 2007-07-31 2009-02-05 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
TWI351288B (en) * 2008-07-04 2011-11-01 Univ Nat Pingtung Sci & Tech Cpg dna adjuvant in avian vaccines
AU2009283557B2 (en) * 2008-08-18 2013-01-17 Kitasato Daiichi Sankyo Vaccine Co., Ltd. Avian influenza virus antigen, and booster immunization method for avian influenza vaccine in combination with mucosal adjuvant which is effective through oral administration
KR101634058B1 (ko) * 2008-12-09 2016-06-27 화이자 백신스 엘엘씨 ＩｇＥ ＣＨ３ 펩티드 백신
BRPI1014494A2 (pt) * 2009-04-30 2016-08-02 Coley Pharm Group Inc vacina pneumocócica e usos da mesma
WO2012160183A1 (en) * 2011-05-26 2012-11-29 Intervet International B.V. Immunostimulatory oligodeoxynucleotides

Also Published As

Publication number Publication date
US20140199345A1 (en) 2014-07-17
CN103547674A (zh) 2014-01-29
MX346596B (es) 2017-03-23
RU2587633C2 (ru) 2016-06-20
EP2714907B1 (en) 2016-06-15
BR112013029968A2 (pt) 2017-01-31
WO2012160183A1 (en) 2012-11-29
ZA201308479B (en) 2014-08-27
CA2834442A1 (en) 2012-11-29
JP5872684B2 (ja) 2016-03-01
JP2014516533A (ja) 2014-07-17
RU2013156635A (ru) 2015-07-10
US9359602B2 (en) 2016-06-07
EP2714907A1 (en) 2014-04-09

Similar Documents

Publication Publication Date Title
MX2013007657A (es) Oligodesoxinucleotidos inmunoestimulantes.
MX2013013800A (es) Oligodesoxinucleotidos inmunoestimuladores.
MX2013013801A (es) Oligodesoxinucleotidos inmunoestimuladores.
MX352324B (es) Vacunas multivalentes de nanovehiculos sinteticos.
EP2706991A4 (en) IMMUNOGENIC COMPOSITION HAVING MULTIPLE ANTIGENS, METHODS AND USES THEREOF
TN2012000414A1 (en) Forms of rifaximin and uses thereof
PH12016501122A1 (en) Delayed release compositions of linaclotide
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
ZA201309386B (en) Vaccine composition comprising an inactivated chikungunya virus strain
MX2013004061A (es) Analogos de ciclosporina.
ZA201404199B (en) Compositions, comprising improved il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same.
MX356210B (es) Formulaciones de polimero acrilico.
MD20120127A2 (en) Recombinant Koi herpesvirus (KHV), method for its production and vaccine for the prevention of a disease caused by KHV
CA2915027A1 (en) Compositions and methods for administration of vaccines against dengue virus
MX2013004062A (es) Analogos de ciclosporina.
IN2015MN00038A (es)
EP2931310A4 (en) COMPOSITIONS, METHODS OF ADMINISTRATION AND USES OF TRIVALENT FORMULATIONS AGAINST DENGUE VIRUS
MX2013003245A (es) Vacuna contra virus de diarrea viral de bovinos.
MX2014015766A (es) Receptores de tipo toll y oligonucleotidos inmunoestimuladores.
HK1207563A1 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
PL2569007T3 (pl) Szczepionka przeciwko Mycoplasma Hyopneumoniae, odpowiednia do podawania w obecności przeciwciał pochodzących od matki
GB2515222A (en) Use of flagellin as a vaccine
MX350718B (es) Vacuna de rinitis equina.
HK1255682A1 (zh) 改性馬立克氏病病毒及從其製備的疫苗
HK1209027A1 (en) Vesicular formulations, uses and methods

Legal Events

Date Code Title Description
FG Grant or registration